ValiRx plc (LON:VAL – Get Free Report) shares reached a new 52-week low during trading on Thursday . The stock traded as low as GBX 3.23 ($0.04) and last traded at GBX 3.30 ($0.04), with a volume of 607805 shares changing hands. The stock had previously closed at GBX 3.45 ($0.04).
ValiRx Trading Down 4.3 %
The company has a 50 day simple moving average of GBX 3.84 and a 200 day simple moving average of GBX 6.64. The company has a current ratio of 13.37, a quick ratio of 1.27 and a debt-to-equity ratio of 0.73. The stock has a market capitalization of £4.37 million, a PE ratio of -110.00 and a beta of 0.63.
About ValiRx
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer.
Featured Stories
- Five stocks we like better than ValiRx
- 3 REITs to Buy and Hold for the Long Term
- Hasbro’s Management Made All the Right Calls This Quarter
- 3 Stocks to Consider Buying in October
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- When to Sell a Stock for Profit or Loss
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for ValiRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx and related companies with MarketBeat.com's FREE daily email newsletter.
